Prevention of cardiac dysfunction during adjuvant breast cancer therapy (PRADA): A 2 × 2 factorial, randomized, placebo-controlled, double-blind clinical trial of candesartan and metoprolol

European Heart Journal

Volumn 37, Issue 21, 2016, Pages 1671-1680

  Gulati, Geeta ^a,b   Heck, Siri Lagethon ^a,b   Ree, Anne Hansen ^a,b   Hoffmann, Pavel ^c   Schulz Menger, Jeanette ^d,e   Fagerland, Morten W ^f   Gravdehaug, Berit ^a   Von Knobelsdorff Brenkenhoff, Florian ^d   Bratland, Åse ^g   Storås, Tryggve H ^f   Hagve, Tor Arne ^a,b   Røsjø, Helge ^a,b   Steine, Kjetil ^a,b   Geisler, Jürgen ^a,b   Omland, Torbjørn ^a,b  

^a AKERSHUS UNIVERSITY HOSPITAL   (Norway)

^b UNIVERSITY OF OSLO   (Norway)

^c ULLEVÅL UNIVERSITY HOSPITAL   (Norway)

^d CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^e HELIOS Clinic Berlin Buch   (Germany)

^f OSLO UNIVERSITY HOSPITAL   (Norway)

^g OSLO UNIVERSITY HOSPITAL   (Norway)

Author keywords

Angiotensin antagonist; b Blocker; Biomarkers; Breast cancer; Cardiomyopathy; Imaging

Indexed keywords

ANTHRACYCLINE; CANDESARTAN HEXETIL; CYCLOPHOSPHAMIDE; EPIRUBICIN; FLUOROURACIL; METOPROLOL SUCCINATE; PLACEBO; TRASTUZUMAB; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTINEOPLASTIC AGENT; BENZIMIDAZOLE DERIVATIVE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BIPHENYL DERIVATIVE; METOPROLOL; TETRAZOLE DERIVATIVE;

ADJUVANT THERAPY; ADULT; ARTICLE; BREAST CANCER; CANCER ADJUVANT THERAPY; CARDIAC DYSFUNCTION; CARDIOVASCULAR MAGNETIC RESONANCE; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; FEMALE; HEART DISEASE; HUMAN; INTENTION TO TREAT ANALYSIS; MAJOR CLINICAL STUDY; MIDDLE AGED; NUCLEAR MAGNETIC RESONANCE SCANNER; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; UNSPECIFIED SIDE EFFECT; ADJUVANT CHEMOTHERAPY; BREAST TUMOR; COMBINATION DRUG THERAPY; HEART FAILURE; TREATMENT OUTCOME;

ADRENERGIC BETA-ANTAGONISTS; ANGIOTENSIN RECEPTOR ANTAGONISTS; ANTHRACYCLINES; ANTINEOPLASTIC AGENTS; BENZIMIDAZOLES; BIPHENYL COMPOUNDS; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; FEMALE; HEART FAILURE; HUMANS; METOPROLOL; MIDDLE AGED; TETRAZOLES; TRASTUZUMAB; TREATMENT OUTCOME;

EID: 84973281958     PISSN: 0195668X     EISSN: 15229645     Source Type: Journal    
DOI: 10.1093/eurheartj/ehw022     Document Type: Article

References (30)

1. Ewer MS, Ewer SM. Cardiotoxicity of anticancer treatments. Nat Rev Cardiol 2015; 12:547-558.
2. Drafts BC, Twomley KM, D'Agostino R, Lawrence J, Avis N, Ellis LR, Thohan V, Jordan J, Melin SA, Torti FM, Little WC, Hamilton CA, Hundley WG. Low to moderate dose anthracycline-based chemotherapy is associated with early noninvasive imaging evidence of subclinical cardiovascular disease. JACC Cardiovasc Imaging 2013;6:877-885.
3. Chien KR. Herceptin and the heart-a molecular modifier of cardiac failure. N Engl J Med 2006;354:789-790.
4. Tan TC, Neilan TG, Francis S, Plana JC, Scherrer-Crosbie M. Anthracycline-induced cardiomyopathy in adults. Compr Physiol 2015;5:1517-1540.
5. Vejpongsa P, Yeh ET. Prevention of anthracycline-induced cardiotoxicity: challenges and opportunities. J Am Coll Cardiol 2014;64:938-945.
6. Cardinale D, Colombo A, Bacchiani G, Tedeschi I, Meroni CA, Veglia F, Civelli M, Lamantia G, Colombo N, Curigliano G, Fiorentini C, Cipolla CM. Early detection of anthracycline cardiotoxicity and improvement with heart failure therapy. Circulation 2015;131:1981-1988.
7. Suter TM, Ewer MS. Cancer drugs and the heart: importance and management. Eur Heart J 2013;34:1102-1111.
8. The SOLVD Investigators. Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions. N Engl J Med 1992;327:685-691.
9. The SOLVD Investigators. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med 1991;325:293-302.
10. Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF). Lancet 1999; 353:2001-2007.
11. Hahn VS, Lenihan DJ, Ky B. Cancer therapy-induced cardiotoxicity: basic mechanisms and potential cardioprotective therapies. J Am Heart Assoc 2014;3: e000665.
12. Seicean S, Seicean A, Alan N, Plana JC, Budd GT, Marwick TH. Cardioprotective effect of beta-adrenoceptor blockade in patients with breast cancer undergoing chemotherapy: follow-up study of heart failure. Circ Heart Fail 2013;6: 420-426.
13. Cardinale D, Colombo A, Sandri MT, Lamantia G, Colombo N, Civelli M, Martinelli G, Veglia F, Fiorentini C, Cipolla CM. Prevention of high-dose chemotherapy-induced cardiotoxicity in high-risk patients by angiotensinconverting enzyme inhibition. Circulation 2006;114:2474-2481.
14. Bosch X, Rovira M, Sitges M, Domenech A, Ortiz-Perez JT, de Caralt TM, Morales-Ruiz M, Perea RJ, Monzo M, Esteve J. Enalapril and carvedilol for preventing chemotherapy-induced left ventricular systolic dysfunction in patients with malignant hemopathies: the OVERCOME trial (preventiOn of left Ventricular dysfunction with Enalapril and caRvedilol in patients submitted to intensive ChemOtherapy for the treatment of Malignant hEmopathies). J Am Coll Cardiol 2013;61:2355-2362.
15. Kalay N, Basar E, Ozdogru I, Er O, Cetinkaya Y, Dogan A, Inanc T, Oguzhan A, Eryol NK, Topsakal R, Ergin A. Protective effects of carvedilol against anthracycline-induced cardiomyopathy. J Am Coll Cardiol 2006;48:2258-2262.
16. Dessi M, Piras A, Madeddu C, Cadeddu C, Deidda M, Massa E, Antoni G, Mantovani G, Mercuro G. Long-term protective effects of the angiotensin receptor blocker telmisartan on epirubucin-induced inflammation, oxidative stress and myocardial dysfunction. Exper Therapeutic Med 2011;2:1003-1009.
17. Kaya MG, Ozkan M, Gunebakmaz O, Akkaya H, Kaya EG, Akpek M, Kalay N, Dikilitas M, Yarlioglues M, Karaca H, Berk V, Ardic I, Ergin A, Lam YY. Protective effects of nebivolol against anthracycline-induced cardiomyopathy: a randomized control study. Int J Cardiol 2013;167:2306-2310.
18. Yun S, Vincelette ND, Abraham I. Cardioprotective role of beta-blockers and angiotensin antagonists in early-onset anthracyclines-induced cardiotoxicity in adult patients: a systematic review and meta-analysis. Postgrad Med J 2015;91: 627-633.
19. Heck SL, Gulati G, Ree AH, Schulz-Menger J, Gravdehaug B, Rosjo H, Steine K, Bratland A, Hoffmann P, Geisler J, Omland T. Rationale and design of the prevention of cardiac dysfunction during an adjuvant breast cancer therapy (PRADA) trial. Cardiology 2012;123:240-247.
20. Schulz-Menger J, Bluemke DA, Bremerich J, Flamm SD, Fogel MA, Friedrich MG, Kim RJ, von Knobelsdorff-Brenkenhoff F, Kramer CM, Pennell DJ, Plein S, Nagel E. Standardized image interpretation and post processing in cardiovascular magnetic resonance: Society for Cardiovascular Magnetic Resonance (SCMR) board of trustees task force on standardized post processing. J Cardiovasc Magn Reson 2013;15:35.
21. Omland T, Pfeffer MA, Solomon SD, de Lemos JA, Rosjo H, Saltyte Benth J, Maggioni A, Domanski MJ, Rouleau JL, Sabatine MS, Braunwald E. Prognostic value of cardiac troponin I measured with a highly sensitive assay in patients with stable coronary artery disease. J Am Coll Cardiol 2013;61:1240-1249.
22. Apple FS, Collinson PO. Analytical characteristics of high-sensitivity cardiac troponin assays. Clin Chem 2012;58:54-61.
23. Altena R, Perik PJ, van Veldhuisen DJ, de Vries EGE, Gietema JA. Cardiovascular toxicity caused by cancer treatment: strategies for early detection. Lancet Oncol 2009;10:391-399.
24. Nikitovic D, Juranek I, Wilks MF, Tzardi M, Tsatsakis A, Tzanakakis GN. Anthracycline-dependent cardiotoxicity and extracellular matrix remodeling. Chest 2014;146:1123-1130.
25. Plana JC, Galderisi M, Barac A, Ewer MS, Ky B, Scherrer-Crosbie M, Ganame J, Sebag IA, Agler DA, Badano LP, Banchs J, Cardinale D, Carver J, Cerqueira M, DeCara JM, Edvardsen T, Flamm SD, Force T, Griffin BP, Jerusalem G, Liu JE, Magalhaes A, Marwick T, Sanchez LY, Sicari R, Villarraga HR, Lancellotti P. Expert consensus for multimodality imaging evaluation of adult patients during and after cancer therapy: a report from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. Eur Heart J Cardiovasc Imaging 2014;15:1063-1093.
26. Silke B, Verma SP, Midtbo KA, Muller P, Frais MA, Reynolds G, Taylor SH. A haemodynamic study of the effects of combined slow-calcium channel blockade (nisoldipine) and beta-blockade (metoprolol) in coronary heart disease. Int J Cardiol 1986; 13:231-241.
27. Luchner A, Burnett JJC, Jougasaki M, Hense H-W, Riegger GAJ, Schunkert H. Augmentation of the cardiac natriuretic peptides by beta-receptor antagonism: evidence from a population-based study. J Am Coll Cardiol 1998;32: 1839-1844.
28. Wu AHB. Serial testing of B-type natriuretic peptide and NTpro-BNP for monitoring therapy of heart failure: the role of biologic variation in the interpretation of results. Am Heart J 2006;152:828-834.
29. Putt M, Hahn VS, Januzzi JL, Sawaya H, Sebag IA, Plana JC, Picard MH, Carver JR, Halpern EF, Kuter I, Passeri J, Cohen V, Banchs J, Martin RP, Gerszten RE, Scherrer-Crosbie M, Ky B. Longitudinal changes in multiple biomarkers are associated with cardiotoxicity in breast cancer patients treated with doxorubicin, taxanes, and trastuzumab. Clin Chem 2015;61:1164-1172.
30. Cardinale D, Colombo A, Lamantia G, Colombo N, Civelli M, De Giacomi G, Rubino M, Veglia F, Fiorentini C, Cipolla CM. Anthracycline-induced cardiomyopathy: clinical relevance and response to pharmacologic therapy. J Am Coll Cardiol 2010;55:213-220.